Project

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)

Ongoing - recruitment closed · 0023 until 2030

Aeppli Stefanie, Sennhauser Andrina, Frehner Jan